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Abstract
According to Brazilian National Data Survey diabetes is the fifth cause for hospitalization and is one
of the ten major causes of mortality in this country.
Aims
to stratify the estimated cardiovascular risk (eCVR) in a population of type 2 diabetics (T2DM)
according to the Framingham prediction equations as well as to determine the association between
eCVR with metabolic and clinical control of the disease.
Methods
From 2000 to 2001 a cross-sectional multicenter study was conducted in 13 public out-patients
diabetes/endocrinology clinics from 8 Brazilian cities. The 10-year risk of developing coronary heart
disease (CHD) was estimated by the prediction equations described by Wilson et al (Circulation
1998). LDL equations were preferably used; when patients missed LDL data we used total
cholesterol equations instead.
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Data from 1382 patients (59.0% female) were analyzed. Median and inter-quartile range (IQ) of age
and duration of diabetes were 57.4 (51-65) and 8.8 (3-13) years, respectively without differences
according to the gender. Forty-two percent of these patients were overweight and 35.4% were
obese (the prevalence of higher BMI and obesity in this T2DM group was significantly higher in
women than in men; p < 0.001). The overall estimated eCVR in T2DM patients was 21.4 (13.5-
31.3). The eCVR was high (> 20%) in 738 (53.4%), intermediate in 202 (14.6%) and low in 442 (32%)
patients. Men [25.1(15.4-37.3)] showed a higher eCVR than women [18.8 (12.4-27.9) p < 0.001].
The most common risk factor was high LDL-cholesterol (80.8%), most frequently found in women
than in men (p = 0.01). The median of risk factors present was three (2-4) without gender
differences. Overall we observed that 60 (4.3%) of our patients had none, 154(11.1%) one, 310
(22.4%) two, 385 (27.9%) three, 300 (21.7%) four, 149 (10.5%) five and six, (2%) six risk factors. A
higher eCVR was noted in overweight or obese patients (p = 0.01 for both groups). No association
was found between eCVR with age or a specific type of diabetes treatment. A correlation was
found between eCVR and duration of diabetes (p < 0.001), BMI (p < 0.001), creatinine (p < 0.001)
and triglycerides levels (p < 0.001) but it was not found with HbA1c, fasting blood glucose and post-
prandial glucose. A higher eCVR was observed in patients with retinopathy (p < 0.001) and a
tendency in patients with microalbuminuria (p = 0.06). Conclusion: our study showed that in this
group of Brazilian T2DM the eCVR was correlated with the lipid profile and it was higher in patients
with microvascular chronic complications. No correlation was found with glycemic control
parameters. These data could explain the failure of intensive glycemic control programs aiming to
reduce cardiovascular events observed in some studies.
Introduction
The prevalence of diabetes is increasing quickly in devel-
oping countries because of changes in lifestyle that have
occurred in the last decades. According to the estimates
provided by the World Health Organization (WHO), by
the year 2025 more than 75% of people with diabetes will
be living in developing countries [1]. The majority of peo-
ple with diabetes in these countries will be aged between
45-65 years, that corresponds to the most productive
period of their lives. The last demographic census in Brazil
has estimated a population of approximately 170 million
people [2] with many people between 45-65 years. The
prevalence of diabetes was estimated to be of 7.6% in a
multicenter study conducted in 1988 [3]. Although WHO
has estimated a prevalence of diabetes in our country of
7.2% by the year of 2025, more recent data, though scarce
and limited to some regions, showed a prevalence of
12.5% in 1999 [4]. According to Brazilian National Data
Survey, diabetes is the fifth cause for hospitalization and
is one of the ten major causes of mortality in this country
[5].
Lately, a better management of the disease has resulted in
a longer survival of patients with type 2 diabetes and in a
rising prevalence of chronic complications, mainly those
cardiovascular [6]. According to different studies the lead-
ing cause of death in more than 50% of these patients will
be coronary artery disease [7]. Patients with type 2 diabe-
tes have a two to six-fold higher incidence of coronary
artery disease and stroke and are considered as having a
risk equivalent of a non-diabetic patient with pre-existing
heart disease [8]. Moreover, the prognosis of patients with
diabetes who have a cardiovascular disease is much worse.
The economic impact of the above -mentioned facts will
have implications in National Health Care Systems
increasing the direct and indirect costs of the disease [9].
It is estimated that 85% of the costs with complications
resulting from type 2 diabetes are related to cardiovascular
disease [9].
The most well known methods to identify cardiovascular
risk are the mathematical equations developed by the
Framingham heart study. This study has established a
score for prediction of the risk for CVD in 10 years using
simple clinical and laboratory variables [10].
The purpose of our study was to stratify the cardiovascular
risk in a population of type 2 diabetic patients according
to the Framingham prediction equations and to deter-
mine if there is a geographical variation in our country.
The secondary purpose was to evaluate the association
between cardiovascular risk and metabolic and clinical
parameters of diabetes control.
Research Design and Methods
This cross-sectional multicenter study was conducted
between May 2000 and May 2001 in thirteen public spe-
cialty clinics (diabetes/endocrinology) from eight Brazil-
ian cities. Each clinic has provided data from at least 100
consecutive regularly attending out-patients with type 2Page 2 of 7
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one visit yearly, mainly in the last six months and who
have been followed at each center for at least one year. For
each patient, data for the most recent clinic visit were col-
lected using standardized chart review forms. A clinical
visit was defined as a visit with physical examination by a
physician. Patients were considered to have type 2 diabe-
tes when it was diagnosed with an age ≥ 30 years, without
insulin use in the first year after the diagnosis and without
history of ketosis or ketonuria. The following variables
were assessed from the most recent clinical visit: age, dura-
tion of diabetes, BMI, blood pressure (systolic and diasto-
lic), HBA1c, fasting and post-prandial glucose, total
cholesterol, HDL-cholesterol, LDL-cholesterol, triglycer-
ides and therapeutic regimen of diabetes. For each patient
we recorded if funduscopy, microalbuminuria and foot
examination were done in the prior year or at the most
recent clinical visit as recommended by Brazilian Diabetes
Society. For this study, five antidiabetic therapeutic regi-
mens were defined: diet, oral antidiabetic drugs, combina-
tion of oral antidiabetic drugs, combination of insulin
plus oral antidiabetic drugs and insulin as monotherapy.
Sex -specific prediction equations for cardiovascular dis-
ease were calculated according to age, diabetes, smoking
status, blood pressure (JNC-V categories) and total choles-
terol and LDL-cholesterol (NCEP ATP III categories). The
10-year risk of developing coronary heart disease (CHD)
was estimated by the prediction equations described by
Wilson et al [10] LDL equations were preferably used;
when patients missed LDL data, we used total cholesterol
equations instead.
When triglycerides were ≤ 400 mg/dL the concentration of
LDL cholesterol was estimated indirectly by use of Fried-
wald formula [11].
We used the recommendations defined by BDS to assess if
our patients reached the goals for metabolic and clinical
control of diabetes [12].
This study was approved by local ethics committee.
Categorical variables were summarized as count and per-
centage, and numerical variables as median and inter-
quartile range. The Kruskal-Wallis and Mann-Whitney U
tests were used for comparisons between groups of varia-
bles not normally distributed and the Student t-test and
ANOVA were used for the other comparisons. The Chi-
square test with Yates correction were used for compari-
son of categorical variables; the correlation between
numerical variables was tested with the Spearman's corre-
lation (rho). Stepwise multivariate regression analysis was
done with estimated Framingham risk as dependent vari-
able and variables with p < 0.1 in Spermann's correlation.
Statistical analyses were performed with Stata version 10
(StataCorp, 2007).
Results
Data from 1382 (n = 815; 59.0% female) were analyzed.
Median and inter-quartile range of age and duration of
diabetes were 57.4 (51-65) and 8.8 (3-13) years, respec-
tively, without differences according to gender The base-
line data of the patients are described in table 1. All
patients received health care from National Brazilian
Health Care System (NBHCS) and most had a low income
and education level, similar as in another previous Brazil-
ian survey [12]. Two-thirds of the patients were over-
weight (42.3%) or obese (35.4%). Women had a
significantly higher BMI [28.8 (25.6-32.2 kg/m2) than
men (27.7 (25-30.1) kg/m2) p < 0.001] and a higher prev-
alence of obesity (41.1.0% vs. 27.2%, p < 0.001).
Table 1: Baseline data of the patients
Variable
N 1382
Gender (female) n(%) 815(59)
Age (years) 57.4 ± 9.4
Diabetes duration (years) 8.8 ± 7.2
HbA1 or HbA1c (%) 8.7 ± 2.2
BMI(kg/m2) 28.6 ± 5.1
FPG (mg/dL) 168.3 ± 71.2
PPPG (mg/dL) 199.8 + 88.6
sBP (mm Hg) 140.7 ± 22.8
dBP (mm Hg) 84.4 ± 11.3
Total cholesterol (mg/dL) 211.3 ± 42.8
Triglycerides (mg/dL) 177.5 ± 125.2
HDL(mg/dL) 44.7 ± 12.6
LDL cholesterol (mg/dL) * 130 ± 38.8
Retinopathy(yes/no) ** 551/497
Albumin Excretion rate (ug/min) 20 (0.03-4580)
Data are means ± SD, n (%). sBP, systolic blood pressure; dBP, 
diastolic blood pressure; BMI, body mass index; FPG, fasting blood 
glucose; PPG, postprandial glucose; total cholesterol;* LDL was not 
calculated if triglycerides > 4.5 mmol/l(n = 83); **n = 1058Page 3 of 7
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visit was not documented in 208(15%) of the clinical
files. Diet alone n = 103(7.5%), one OHA n = 399
(28.9%), OHA combination therapy n = 234 (16.9%),
OHA plus insulin = 278 (20.1%) and insulin as mono-
therapy n = 160 (11.6%) were the used therapeutic regi-
mens.
The overall estimated risk was 21.4 (13.5-31.3) 95% CI
(20.4-22.2) figure 1. A high risk (> 20%) was found in 738
patients (53.4%), a intermediate risk in 202 (14.6%) and
a low risk in 442 (32%). More men than women [360
(63.5%) vs 378 (46.4%) p < 0.001] were classified as
being at high risk. Men had a higher estimated risk than
women, respectively [25.1(15.4-37.3) vs 18.8 (12.4-27.9)
p < 0.001] figure 1. Among patients the most common
risk factor was high LDL-cholesterol (80.8%) with a
higher frequency in women than men ([687(83.1%) vs
440 (77.6%) p = 0.01]. The median of the number of risk
factors present was three (2-4) without difference between
men and women. Finally, we observed that 60 (4.3%) of
our patients had no risk factor, 154 (11.1%) had one, 310
(22.4%) had two, 385 (27.9%) had three, 300 (21.7%)
had four, 149 (10.5%) had five and six (2%) had six risk
factors. This distribution was similar in men and women
(p > 0.5).
A higher estimated risk was noted in overweight or obese
patients, respectively [21.4 (14.8-31.3) vs. 20.7 (12.7-
30.7) vs kg/m2 p = 0.01). We noted a linear trend between
estimated risk and geographic region of the country
respectively southwest, northwest, south and central
[24.1(15.5-34.0) vs 20.6 (12.3-30.8) vs.19.9 (13.4-30.1)
vs. 14.9 (10.9-21.6) p = 0.000] figure 2. No differences
were found between estimated risk and age, and type of
diabetes treatment. A higher estimated risk was observed
in patients with retinopathy, [24.9 (16.3-35.3 vs
18.3(11.4-28.6) % p < 0.001] and a tendency in patients
with microalbuminuria, respectively [27.8 (14.6-38.9) vs
22.7(15.7-32.9)% p = 0.06].
A correlation was found between estimated risk and dura-
tion of diabetes (rho 0.11 p < 0.001), BMI (rho = 0.11 p <
0.001), creatinine (rho = 0.40 p < 0.001), HDL-choles-
terol (rho = - 0.38 p < 0.001) and triglycerides levels (rho
= 0.26 p < 0.001). No correlation was found between esti-
mated risk and HBA1c, fasting blood glucose and post-
prandial glucose.
In the pooled group a stepwise multiple regression analy-
sis applied to the data with estimated Framingham risk as
dependent variable showed HDL-cholesterol, creatinine,
gender (male), retinopathy, triglycerides and HbA1c as
the significant independent variables. These data are
shown in table 2.
Discussion
According to our results the majority of our patients with
type 2 diabetes are at a high risk of CHD (> 20% in 10
years). Recently a study has compared the performance of
Framingham equation and the UKPDS risk engine for the
estimated cardiovascular (CV) risk in 10 years [13]. The
UKPDS risk engine is a type 2 diabetes specific risk calcu-
lator which uses measures of glycemia (HbA1c) and dura-
tion of known diabetes as continuous variables in
addition to the usual cardiovascular risk factors. Neverthe-
less, this study has concluded that Framingham equation
significantly underestimated the CV risk in 10 years, but
only in 2% [13].Estimated Framingham risk according to genderFigure 1
Estimated Framingham risk according to gender.
Estimated Framingham risk according to geographic regionFigure 2
Estimated Framingham risk according to geographic 
region.Page 4 of 7
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comparison to women. Although some studies have
shown a high cardiovascular mortality in women [14,15],
a recent meta-analysis with sixteen studies showed that
the excess relative risk of cardiovascular (CHD) mortality
in women vs men disappeared after adjusting for CHD
risk factors, having men still more cardiovascular death
attributable to diabetes than women [16]. We observed
that women were less likely than men to meet the goals
for LDL cholesterol which should focus the attention on
gender-specific treatment. Some studies showed similar
results and this was mainly related to less aggressive treat-
ment in women [17,18].
We have observed a linear trend between higher estimated
risk and geographic regions of our country, however we
could not identify which one was responsible for this
higher risk (figure 2). Our country has a great racial mis-
cegenation resulting probably in different nutritional hab-
its and different behaviors related to physical activities,
smoking and other habits not yet identified. All the above-
mentioned could have influenced in the estimated cardi-
ovascular risk.
Similar to the results found in other studies, [19-21] we
found higher estimated cardiovascular risk in patients
with microvascular complications defined as categorical
variables. The positive correlation with plasma creatinine
levels should indirectly reflect an association with low
glomerular filtration rate and renal function. Many stud-
ies have shown that albuminuria is a significant inde-
pendent predictor of cardiovascular disease, worsening
the prognosis of patients with diabetes [19,20]. We also
observed a high estimated cardiovascular risk in patients
with retinopathy, a marker of microvascular disease.
Recent study has demonstrated a link between retinopa-
thy, with the worsening of cardiac structure and function
by echocardiography independent of potential confound-
ing variables [21]. In this study it was also noted a trend
between the severity of retinopathy and the decrease of
left ventricular ejection fraction.
Overall more than 75% of our sample had ≥ 2 risk factors
without difference according to gender. However, consid-
ering that diabetes per se is an important cardiovascular
risk factor we can conclude that more than 90% of our
sample had ≥ 2 risk factors. Several studies have shown
that diabetic patients have more cardiovascular risk fac-
tors than non-diabetic individuals [22-25]. In our study,
the most common risk factor was high LDL-cholesterol
similar to the results of the Strong Heart Study which is an
American Indian population based study [26]. This study
concluded that for each 10-mg/dL increase in LDL-choles-
terol corresponded to a 12% increase in cardiovascular
risk, and a 10-mg/dL decrease in HDL-cholesterol was
associated with a 22% increase in cardiovascular risk. This
latter information was also observed in our study because
HDL-cholesterol was the most important independent
variable in the model used for multivariate analysis.
In a previous study, we have demonstrated that the major-
ity of our patients with type 2 diabetes attending public
specialty clinics did not met the targets for all the cardio-
vascular risk factors [25]. Our data showed that there is a
gap between the reality of routine diabetes care and the
guidelines established by the BDS similar to that observed
worldwide.
Considering all the different parameters to evaluate glyc-
emic control (HbA1c, fasting and post-breakfast glucose)
our study observed only a weak correlation between
HbA1c and the estimated cardiovascular risk. Although
different, well done clinical trials have demonstrated
definitively that good glycemic control can reduce the risk
of microvascular complications in patients with type 1
diabetes as well as with type 2 diabetes [27-29] this is
uncertain in relation to cardiovascular disease in patients
with type 2 diabetes [28]. Several recent large and long-
term trials with patients at relatively high risk failed to
demonstrate the effects of intensive glycemic control in
comparison to standard one on cardiovascular outcomes
[30-32]. Recently it was pointed out that for prevention of
cardiovascular disease in patients with diabetes type 2 we
Table 2: Stepwise multiple regression with estimated Framingham risk as dependent variable in the total population studied
Regression analysis
Independent variables B Adjusted R2 95%-CI p values
HDL-cholesterol (mg/dL) -0.001 0.14 -0.033 to - 4.17E-04 0.001
Creatinine (mg/dL) 0.05 0.21 0.02 to 0.08 0.001
Gender (male/female) 0.26 0.03 to 0.09 0.002
Retinopathy (yes/no) 0.28 0.006 to 0.04 0.01
Triglycerides (mg/dL) 2.15E-04 0.30 6.14 E-05 to 3.7 E-04 0.006
HbA1c (%) -0.006 0.32 -0.01 to -6.3E-04 0.03
As gender and retinopathy were categorical variables the B value can not be calculatedPage 5 of 7
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approach. In this context the Steno -2 study which was
based in a multifactorial aggressive intervention in differ-
ent cardiovascular risk factors like hyperglycemia, dyslipi-
demia and high blood pressure, in patients with type 2
diabetes with albuminuria showed a significant reduction
in cardiovascular events that persisted 5 to 6 years after the
end of the trial [33].
Some limitations of our study must be discussed. The esti-
mated risk derived from the prediction model used is age
adjusted and sex-specific and based in an integration
between blood pressure and cholesterol information with
a weighting approach. Even though our sample com-
prised only patients with type 2 diabetes, a population
with a well known high risk for cardiovascular disease
(CVD), other important variables that increase this risk as
family history of CVD, presence of chronic complications
of diabetes, were not considered in the model. Another
point is that the estimated risk derived from this equation
is continuous as probably is usual for most of the patients.
In conclusion, the results of our study showed that in this
population of patients with type 2 diabetes the estimated
cardiovascular risk was correlated with lipid profile but
not with glycemic control parameters. Patients with
microvascular chronic complications had a higher esti-
mated cardiovascular risk. These data could explain the
failure of intensive glycemic control in reducing cardio-
vascular events observed in some studies.
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